Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy

NCT02978716 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT02978716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02978716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 2, 2017
Completion date
February 28, 2020
Enrollment
102 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasm, triple-negative breast cancer, triple-negative breast neoplasms